Voyager Therapeutics Inc (VYGR) - Total Liabilities
Based on the latest financial reports, Voyager Therapeutics Inc (VYGR) has total liabilities worth $68.49 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore VYGR strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Voyager Therapeutics Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Voyager Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Voyager Therapeutics Inc (VYGR) total assets.
Voyager Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Voyager Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wasko S.A.
WAR:WAS
|
Poland | zł160.96 Million |
|
Lollands Bank
CO:LOLB
|
Denmark | Dkr4.87 Billion |
|
Manulife Holdings Bhd
KLSE:1058
|
Malaysia | RM6.83 Billion |
|
Waterco Ltd
AU:WAT
|
Australia | AU$134.40 Million |
|
Kian Shen Corp
TW:1525
|
Taiwan | NT$809.83 Million |
|
Premium Income Corporation
TO:PIC-A
|
Canada | CA$291.93 Million |
|
PHA Co. Ltd
KQ:043370
|
Korea | ₩278.28 Billion |
|
Silver X Mining Corp
V:AGX
|
Canada | CA$37.68 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Voyager Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Voyager Therapeutics Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Voyager Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Voyager Therapeutics Inc (2013–2024)
The table below shows the annual total liabilities of Voyager Therapeutics Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $93.29 Million | -18.85% |
| 2023-12-31 | $114.96 Million | +14.58% |
| 2022-12-31 | $100.34 Million | +1.55% |
| 2021-12-31 | $98.80 Million | -7.89% |
| 2020-12-31 | $107.26 Million | -57.98% |
| 2019-12-31 | $255.25 Million | +95.47% |
| 2018-12-31 | $130.58 Million | +158.96% |
| 2017-12-31 | $50.43 Million | -6.00% |
| 2016-12-31 | $53.64 Million | -11.16% |
| 2015-12-31 | $60.38 Million | +483.52% |
| 2014-12-31 | $10.35 Million | +159.87% |
| 2013-12-31 | $3.98 Million | -- |
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene the… Read more